Adagene Ownership
| ADAG Stock | USD 1.85 0.02 1.07% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Adagene |
Adagene Stock Ownership Analysis
About 26.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adagene recorded a loss per share of 0.72. The entity had not issued any dividends in recent years. Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company was incorporated in 2011 and is headquartered in Suzhou, China. Adagene Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 259 people. For more info on Adagene please contact the company at 86 512 8777 3632 or go to https://www.adagene.com.Besides selling stocks to institutional investors, Adagene also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Adagene's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Adagene's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Adagene Quarterly Liabilities And Stockholders Equity |
|
About 11.0% of Adagene are currently held by insiders. Unlike Adagene's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Adagene's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Adagene's insider trades
Adagene Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adagene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adagene backward and forwards among themselves. Adagene's institutional investor refers to the entity that pools money to purchase Adagene's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-09-30 | 8.3 K | Ubs Group Ag | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Springbok Capital Management, Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Artal Group S A | 2024-06-30 | 0.0 | Wuxi Apptec Co Ltd | 2024-09-30 | 4 M | Fidelity International Ltd | 2024-09-30 | 3.6 M | Sc China Holding Ltd | 2024-09-30 | 1.3 M | Fmr Inc | 2024-09-30 | 1.3 M |
Adagene Outstanding Bonds
Adagene issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adagene uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adagene bonds can be classified according to their maturity, which is the date when Adagene has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Currently Active Assets on Macroaxis
When determining whether Adagene is a strong investment it is important to analyze Adagene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adagene's future performance. For an informed investment choice regarding Adagene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adagene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Adagene Stock please use our How to Invest in Adagene guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adagene. If investors know Adagene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adagene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth (0.85) | Return On Assets | Return On Equity |
The market value of Adagene is measured differently than its book value, which is the value of Adagene that is recorded on the company's balance sheet. Investors also form their own opinion of Adagene's value that differs from its market value or its book value, called intrinsic value, which is Adagene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adagene's market value can be influenced by many factors that don't directly affect Adagene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adagene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adagene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adagene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.